Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis
<i>Leishmania major</i> (<i>L. major</i>) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/8/11/1803 |
| _version_ | 1797547687578435584 |
|---|---|
| author | Berenice Martínez-Salazar Vanessa Carregaro Pereira Yazmin Hauyon-La-Torre Ali Khamesipour Fabienne Tacchini-Cottier |
| author_facet | Berenice Martínez-Salazar Vanessa Carregaro Pereira Yazmin Hauyon-La-Torre Ali Khamesipour Fabienne Tacchini-Cottier |
| author_sort | Berenice Martínez-Salazar |
| collection | DOAJ |
| description | <i>Leishmania major</i> (<i>L. major</i>) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to administrate. Topical treatment would be the ideal option for the treatment of cutaneous leishmaniasis. MF29 is a 3-haloacetamidobenzoate that was shown in vitro to inhibit tubulin assembly in <i>Leishmania</i>. Here, we tested a topical cream formulated with MF29. BALB/c mice were infected in the ear dermis with <i>L. major</i> metacyclic promastigotes and once the lesion appeared, mice were treated with different concentrations of MF29 and compared to the control group treated with the cream used as the vehicle. We observed that topical application of MF29 reduced the progression of the infection while control groups developed an unhealing lesion that became necrotic. The treatment decreased the type 2 immune response. Comparison with SinaAmphoLeish, another topical treatment, revealed that MF29 treatment once a day was sufficient to control lesion development, while application SinaAmphoLeish needed applications twice daily. Collectively, our data suggest that MF-29 topical application could be a promising topical treatment for cutaneous leishmaniasis. |
| first_indexed | 2024-03-10T14:47:38Z |
| format | Article |
| id | doaj.art-4e997655e0f64653b6bba98b6c930590 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-10T14:47:38Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-4e997655e0f64653b6bba98b6c9305902023-11-20T21:12:38ZengMDPI AGMicroorganisms2076-26072020-11-01811180310.3390/microorganisms8111803Evaluation of a New Topical Treatment for the Control of Cutaneous LeishmaniasisBerenice Martínez-Salazar0Vanessa Carregaro Pereira1Yazmin Hauyon-La-Torre2Ali Khamesipour3Fabienne Tacchini-Cottier4Department of Biochemistry, University of Lausanne, 1066 Epalinges, SwitzerlandDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, SwitzerlandDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, SwitzerlandCentre for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran 14166, IranDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland<i>Leishmania major</i> (<i>L. major</i>) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to administrate. Topical treatment would be the ideal option for the treatment of cutaneous leishmaniasis. MF29 is a 3-haloacetamidobenzoate that was shown in vitro to inhibit tubulin assembly in <i>Leishmania</i>. Here, we tested a topical cream formulated with MF29. BALB/c mice were infected in the ear dermis with <i>L. major</i> metacyclic promastigotes and once the lesion appeared, mice were treated with different concentrations of MF29 and compared to the control group treated with the cream used as the vehicle. We observed that topical application of MF29 reduced the progression of the infection while control groups developed an unhealing lesion that became necrotic. The treatment decreased the type 2 immune response. Comparison with SinaAmphoLeish, another topical treatment, revealed that MF29 treatment once a day was sufficient to control lesion development, while application SinaAmphoLeish needed applications twice daily. Collectively, our data suggest that MF-29 topical application could be a promising topical treatment for cutaneous leishmaniasis.https://www.mdpi.com/2076-2607/8/11/1803<i>Leishmania</i><i>L. major</i>topical treatmentMF-29anti-leishmanial drug |
| spellingShingle | Berenice Martínez-Salazar Vanessa Carregaro Pereira Yazmin Hauyon-La-Torre Ali Khamesipour Fabienne Tacchini-Cottier Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis Microorganisms <i>Leishmania</i> <i>L. major</i> topical treatment MF-29 anti-leishmanial drug |
| title | Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis |
| title_full | Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis |
| title_fullStr | Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis |
| title_full_unstemmed | Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis |
| title_short | Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis |
| title_sort | evaluation of a new topical treatment for the control of cutaneous leishmaniasis |
| topic | <i>Leishmania</i> <i>L. major</i> topical treatment MF-29 anti-leishmanial drug |
| url | https://www.mdpi.com/2076-2607/8/11/1803 |
| work_keys_str_mv | AT berenicemartinezsalazar evaluationofanewtopicaltreatmentforthecontrolofcutaneousleishmaniasis AT vanessacarregaropereira evaluationofanewtopicaltreatmentforthecontrolofcutaneousleishmaniasis AT yazminhauyonlatorre evaluationofanewtopicaltreatmentforthecontrolofcutaneousleishmaniasis AT alikhamesipour evaluationofanewtopicaltreatmentforthecontrolofcutaneousleishmaniasis AT fabiennetacchinicottier evaluationofanewtopicaltreatmentforthecontrolofcutaneousleishmaniasis |